Abstract：Objective: To investigate the expression of vascular endothelial growth factor in breast cancer patients with different body mass index and its effect on prognosis. Methods:450 cases of female breast cancer patients who met the criteria for surgical treatment from January 2016 to January 2017 were selected as the study subjects. They were divided into the normal body mass index group (18 kg/m2< BMI < 25kg/m2) and the obesity group (BMI ≥ 25kg/m2) according to their body mass index. Vascular endothelial cell growth factor (VEGF) was detected by standard streptomycetin protein-peroxidase affinity immunohistochemistry in cancer tissues of subjects, and was divided into 4 levels according to the ratio of positive cells in the tissues: No positive cells are negative (-); Positive cells < 20% showed low expression (+). 20%~50% of the positive cells were moderately expressed (++) >50% of the positive cells were highly expressed (+++). - ~ + was regarded as low expression of vascular endothelial growth factor, while ++ ~ ++ was highly expressed. All subjects were followed up for 2 years postoperatively, and whether the subjects had recurrence or metastasis during the follow-up period was recorded. Results: The expression of vascular endothelial growth factor (VEGF) was 38.9% in the normal BMI group and 75.4% in the overweight and obese groups. In the patients with normal BMI, there was no statistically significant difference in 2-year disease-free survival between the patients with high VEGF expression and those with low VEGF expression (P >0.05). In the overweight and obese breast cancer group, the 2-year disease-free survival period of the patients with high VEGF expression was shorter than that of the patients with low VEGF expression, and the difference was statistically significant (P <0.05). Compared with the patients with low VEGF expression in the normal BMI group, the difference in 2-year disease-free survival was statistically significant in the overweight and obese breast cancer group (P <0.05). Compared with patients with high VEGF expression in the normal BMI group, patients with high VEGF expression in the overweight and obese breast cancer group also had a statistically significant difference in 2-year disease-free survival (P <0.05). Conclusion: The expression of vascular endothelial growth factor (VEGF) is increased in obese breast cancer patients, and its expression level is significantly correlated with the prognosis of breast cancer, which suggests that overweight and obese breast cancer patients should actively control their weight to prevent recurrence and metastasis of breast cancer.
李晓锋, 刘希, 汪园园, 张冠军. 血管内皮细胞生长因子在不同BMI乳腺癌患者中的表达及其对预后的影响[J]. 河北医学, 2019, 25(9): 1493-1496.
LI Xiaofeng, LIU Xi, WANG Yuanyuan, et al. Expression of Vascular Endothelial Growth Factor in Breast Cancer Patients with Different BMI and its Effect on Prognosis. HeBei Med, 2019, 25(9): 1493-1496.
[1] Wanqing CHEN, Rongshou ZHENG. Incidence,mortality and survival analysis of breast cancer in China[J]Chinese Journal of Clinical Oncology, 2015, 42(13): 668~674. [2] Haviland J , Owen J , Dewar J , et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.[J]. Lancet Oncology, 2013, 14(11):1086~1094. [3] Chen W , Zheng R . Incidence,mortality and survival analysis of breast cancer in China[J]. Chinese Journal of Clinical Oncology, 2015, 42(13):668~674. [4] Xiang Y J, Guo M M, Zhou C J, et al. Absence of gamma-interferon-inducible lysosomal thiol reductase (GILT) is associated with poor disease-free survival in breast cancer patients.[J]. Plos One, 2014, 9(10):e109449. [5] Fontanella C, Lederer B, Gade S, et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials[J]. Breast Cancer Research & Treatment, 2015, 150(1):127~139. [6] Copson E R , Cutress R I , Maishman T , et al. Obesity and the outcome of young breast cancer patients in the UK: the POSH study[J]. Annals of Oncology, 2015, 26(1):101~112. [7] Soukup V, Capoun O, Pesl M, et al. Placental growth factor in bladder cancer compared to the diagnostic accuracy and prognostic performance of vascular endothelial growth factor a[J]. Anticancer Research, 2018, 38(1):239. [8] Wu M, Xiong H, Xu Y, et al. Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis[J]. Br J Op9hthalmol, 2016, 101(7): 976~984. [9] Thomson A. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer.[J]. Annals of Agricultural & Environmental Medicine Aaem, 2013, 20(2):293~297. [10] Yuan Jingping, Yuan Xiuxue, Gao Likun, et al. Expression of TGF-β1, VEGF and their clinical significance in breast cancer -β1[J]. Chinese journal of endocrine surgery, 2017, 11(5):364.
2019, Vol. 25 
冀公网安备13080202000677号